New hope for advanced prostate cancer: first human trial launches

NCT ID NCT07570979

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen May 13, 2026 · Last updated May 24, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called INR731, alone or with standard hormone therapy, in adults with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 208 participants will take part across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75251, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3000, Australia

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)